Boothbay Fund Management, LLC Rezolute, Inc. Transaction History

Boothbay Fund Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.47 - $4.46 $622,988 - $1.12 Million	252,222 Added 1745.6%	266,671 $1.19 Million
Q1 2025 May 15, 2025	SELL	$2.73 - $5.57 $636,040 - $1.3 Million	-232,982 Reduced 94.16%	14,449 $41,000
Q4 2024 Feb 14, 2025	SELL	$4.08 - $5.96 $35,328 - $51,607	-8,659 Reduced 3.38%	247,431 $1.18 Million
Q3 2024 Nov 14, 2024	SELL	$4.13 - $5.31 $10,985 - $14,124	-2,660 Reduced 1.03%	256,090 $1.24 Million
Q2 2024 Aug 14, 2024	BUY	$2.29 - $5.79 $565,057 - $1.43 Million	246,750 Added 2056.25%	258,750 $1.11 Million

Q1 2023 May 15, 2023	SELL	$1.79 - $2.87 $21,480 - $34,440	-12,000 Reduced 50.0%	12,000 $23,000
Q1 2022 May 16, 2022	SELL	$2.27 - $5.1 $29,332 - $65,902	-12,922 Reduced 35.0%	24,000 $81,000
Q4 2021 Feb 14, 2022	BUY	$4.21 - $7.61 $155,441 - $280,976	36,922 New	36,922 $176,000

124

68.9M

1.01M

57.2K

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $385M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.